Riboflavin/UVA cross-linking has been successfully used in the treatment of non-keratoconus ectasia, such as pellucid marginal degeneration [1,2] or keratectasia following LASIK [3,4] and radial keratotomy . An arrest or even a partial reversal in the ectasia has been seen in almost all cases after cross-linking. There has in fact been only one reported case of an exacerbation of keratectasia despite cross-linking and in this case hormonal changes during pregnancy were believed to be the cause.
 Spadea L. Corneal collagen cross-linking with riboflavin and UVA irradiation in pellucid marginal degeneration. J Refract Surg 2010; 26: 375–377.
 Kymionis G. et al. Management of pellucid marginal corneal degeneration with simultaneous customized photorefractive keratectomy and collagen crosslinking. J Cataract Refract Surg 2009; 35: 1298–1301.
 Kohlhaas M. et al. [A new treatment of keratectasia after LASIK by using collagen with riboflavin/UVA cross-linking]. Article in German. Klin Monastbl Augenheilkd 2005; 222: 430–436.
 Li G. et al. Corneal collagen crosslinking for corneal ectasia of post-LASIK: one-year results. Int J Ophthalmol 2012; 5: 190–195.
 Mazzotta C. et al. Corneal collagen cross-linking to stop corneal ectasia exacerbated by radial keratotomy. Cornea 2011; 30: 225–228.